LXM 12
Alternative Names: LXM-12; LXM.12Latest Information Update: 23 Jan 2025
Price :
$50 *
At a glance
- Originator Laxxon Medical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Prostate cancer
Most Recent Events
- 07 Jan 2025 Early research in Prostate cancer in USA (unspecified route), prior to January 2025 (Laxxon Medical pipeline, January 2025)
- 23 Oct 2024 Laxxon Medical has patent pending for drug supply system in Mexico
- 23 Oct 2024 Laxxon Medical has patent protection for methods of producing a drug delivery system in USA, China, Australia and Japan